Clinical Trials in the Genomic Era: Effects of Protective Genotypes on Sample Size and Duration of Trial
- 29 February 2000
- journal article
- Published by Elsevier in Controlled Clinical Trials
- Vol. 21 (1) , 7-20
- https://doi.org/10.1016/s0197-2456(99)00039-2
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The study of candidate genes in drug trials: sample size considerationsStatistics in Medicine, 1999
- CCR5 promoter polymorphism and HIV-1 disease progressionThe Lancet, 1998
- Antiretroviral Drug Resistance Testing in Adults With HIV InfectionJAMA, 1998
- Genetic Restriction of AIDS Pathogenesis by an SDF-1 Chemokine Gene VariantScience, 1998
- In Search of AIDS-Resistance GenesScientific American, 1997
- Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectinThe Lancet, 1997
- Genes, disease and medicineBritish Journal of Clinical Pharmacology, 1996
- Influence of combinations of human major histocompatibility complex genes on the course of HIV–1 infectionNature Medicine, 1996
- Toward an Understanding of the Correlates of Protective Immunity to HIV InfectionScience, 1996
- The Use of Genetic Information in Large-scale Clinical Trials: Applications to Alzheimer ResearchAlzheimer Disease & Associated Disorders, 1996